Lolamicin
From Wikipedia, the free encyclopedia
| Identifiers | |
|---|---|
3D model (JSmol) |
|
| ChemSpider | |
PubChem CID |
|
| |
| |
| Properties | |
| C24H20N4O | |
| Molar mass | 380.451 g·mol−1 |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
| |
Lolamicin is an experimental antibiotic.[1] It targets Gram-negative bacteria without significantly affecting typical gut microbes.[2] Lolamicin was discovered by a team led by Paul J. Hergenrother at the University of Illinois Urbana-Champaign and was first reported in 2024.[1]
In a mouse model of bacterial infection, lolamicin was found to be especially effective against Escherichia coli, Klebsiella pneumoniae, and Enterobacter cloacae.[3]
Lolamicin works by interfering with the lipoprotein transport system of Gram-negative bacteria.[1]
